

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1.-18. (Canceled)

1 3 (Previously Presented) ^{The} ~~An~~ immunogenic composition according to claim 61, wherein the immunostimulant is an adjuvant.

20.-60. (Canceled)

1 61. (Currently Amended) An immunogenic composition comprising an immunostimulant which induces a predominantly Th1-type immune response and a polypeptide, wherein the polypeptide comprises SEQ ID NO: 113 ~~or a fragment of SEQ ID NO: 113~~ comprising ~~consisting of at least amino acid residues 367-375 of SEQ ID NO: 113~~, and wherein the polypeptide stimulates a human cytotoxic T lymphocyte response specific for SEQ ID NO: 113.

62. (Canceled)

1 2 63. (Previously Presented) ^{The} ~~An~~ immunogenic composition according to claim 61, wherein the immunostimulant is selected from the group consisting of ~~of~~ monophosphoryl lipid A, 3-de-O-acylated monophosphoryl lipid A, and saponins.

64.-65. (Canceled)